CHD5 and central nervous system cancer: Recently, the CHD5 promoter has been found to be methylated in small subsets of breast (4.4%), colon (10%), ovarian (15%) and glioma (17%) tumors [17,20], suggesting epigenetic silencing of CHD5 by methylation may play a partial role in tumorigenesis in these tissues.